Journal
CURRENT PAIN AND HEADACHE REPORTS
Volume 16, Issue 1, Pages 86-92Publisher
SPRINGER
DOI: 10.1007/s11916-011-0233-z
Keywords
Chronic migraine; Episodic migraine; Epidemiological profiles; Sociodemographics; Risk factors; Treatment; Chronic daily headache; Chronification; Diagnosis
Categories
Funding
- Allergan, Inc. (New York, NY)
- Biogen
- Allergan
- Merck Co.
- Bayer
- ENDO Pharmaceuticals
- GlaxoSmithKline
- Bristol-Myers Squibb
Ask authors/readers for more resources
Chronic migraine (CM) and episodic migraine (EM) are part of the spectrum of migraine disorders, but they are distinct clinical entities. Population-based studies have shown that those with CM demonstrate higher individual and societal burden because they are significantly more disabled than those with EM and have greater impaired quality of life both inside and outside the home. Proper diagnosis of both conditions requires clearly defined clinical criteria. Diagnosis enables the initiation of appropriate treatments and risk-factor modification, which ultimately improve functional status and quality of life for persons with migraine. Recognizing that both disorders are on the spectrum of migraine, this review serves as a guide to define the disease state of CM as distinct from EM in terms of clinical, epidemiological, sociodemographic, and comorbidity profiles.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available